Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer~  * Stage III or IV disease~* HLA-A1, -A2, and/or -A3 positive~* Must have at least 1 undissected axillary or inguinal lymph node basin~* No recurrent disease~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Hemoglobin ≥ 8.0 g/dL~* WBC \> 3,000/mm\^3~* Absolute neutrophil count \> 1,500/mm\^3~* Hemoglobin A1c \< 7%~* AST and ALT ≤ 2.5 times upper limit of normal (ULN)~* Bilirubin ≤ 2.5 times ULN~* Creatinine ≤ 1.5 times ULN~* HIV negative~* Hepatitis C negative~* No known or suspected allergies to any component of the study vaccine~* No other concurrent malignancy (except for nonmelanoma skin cancer) unless the patient was curatively treated and has been disease free for ≥ 5 years~* No active serious infection~* No autoimmune disorder with visceral involvement~* No prior or active autoimmune disorders requiring cytotoxic or immunosuppressive therapy~  * The following immunologic conditions are allowed:~    * Laboratory evidence of autoimmune disease (e.g., positive antinuclear antibody titer) without symptoms~   * Clinical evidence of vitiligo~   * Other forms of depigmenting illness~   * Mild arthritis requiring NSAIDs~* No New York Heart Association class III or IV heart disease~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No medical contraindication or potential problem that would preclude study compliance~PRIOR CONCURRENT THERAPY:~* At least 2 weeks since prior and no other concurrent chemotherapy, radiotherapy, or immunotherapy (e.g., interferons, tumor necrosis factor, interleukins, or monoclonal antibodies)~* More than 4 weeks since prior and no other concurrent investigational agents~* More than 4 weeks since prior and no concurrent allergy desensitization injections~* More than 4 weeks since prior and no concurrent oral or parenteral systemic corticosteroids~* No prior or concurrent inhaled corticosteroids (e.g., fluticasone and salmetrol, fluticasone, or triamcinolone acetonide)~  * Prior or concurrent topical corticosteroids allowed~* No prior vaccination with MAGE-A1:161-169, FBP:1901-199, Her-2/neu:369-377, MAGE-A1:96-104, or Her-2/neu:754-762~* More than 4 weeks since prior and no concurrent growth factors (e.g., epoetin alfa, darbepoetin alfa, or pegfilgrastim)~* No concurrent treatment for recurrent disease~* No concurrent nitrosoureas~* No concurrent illegal drug use~* Concurrent nonsteroidal anti-inflammatory drugs (NSAIDs), antihistamines, and chronic medications, unless excluded, are allowed~* Short-term therapy for acute conditions not specifically related to ovarian cancer is allowed

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Patients in group one will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin in week 1. Treatment may repeat every 3 weeks for up to four courses. They will then undergo surgery to remove as much of the tumor as possible. Within 2 weeks after surgery, patients will receive an injection of the vaccine once a week for 3 weeks. Treatment may repeat every 14 weeks for two courses. After finishing the first course of vaccine therapy, patients will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin every 3 weeks for up to four courses.
- Group 2 (Type: EXPERIMENTAL): Patients in group two will undergo surgery to remove as much of the tumor as possible. Within 2 weeks after surgery, patients will receive an injection of the vaccine once a week for 3 weeks. Treatment may repeat every 14 weeks for two courses. After finishing the first course of vaccine therapy, patients will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin every 3 weeks for up to eight courses. Some patients may undergo a second surgery within 6 weeks after completing the fourth course of chemotherapy and undergo tumor and/or lymph node tissue collection.

Based on this trial design, predict the completion outcome and termination type (if applicable).